NCT06482333 Timing of Resumption of Direct Oral Anticoagulants Following Polypectomy
| NCT ID | NCT06482333 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Postpolypectomy Bleeding |
| Study Type | INTERVENTIONAL |
| Enrollment | 194 participants |
| Start Date | 2024-10-03 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 194 participants in total. It began in 2024-10-03 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective randomized non-inferiority trial is to compare two different resumption time of Direct Oral Anticoagulants (DOACs) after colonoscopic polypectomy. We hypothesize that early resumption of DOACs after colonoscopy and polypectomy is associated with comparable post-polypectomy bleeding rate to those with delayed resumption. This study aims to compare the post-polypectomy bleeding risk of two different timing of resuming DOACs (Day 0 vs Day 2):
Eligibility Criteria
Inclusion Criteria: \- All adult patients who are taking DOACs and schedule for elective colonoscopy are potentially eligible. We only included patients who had complete colonoscopy and with polypectomy performed. Exclusion Criteria: * Previous resection of any colonic segments, * Inflammatory bowel disease or polyposis syndrome * Patient with large polyp required advanced procedure e.g. endoscopic submucosal dissection (ESD) to remove * Patients who develop immediate post-polypectomy bleeding during the procedure and requiring haemostasis will also be excluded * Patient without polypectomy * Patient without complete colonoscopy done
Contact & Investigator
Wai Keung Leung
PRINCIPAL INVESTIGATOR
The University of Hong Kong
Frequently Asked Questions
Who can join the NCT06482333 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Postpolypectomy Bleeding. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06482333 currently recruiting?
Yes, NCT06482333 is actively recruiting participants. Contact the research team at waikleung@hku.hk for enrollment information.
Where is the NCT06482333 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT06482333 clinical trial?
NCT06482333 is sponsored by The University of Hong Kong. The principal investigator is Wai Keung Leung at The University of Hong Kong. The trial plans to enroll 194 participants.